Thermo Fisher Scientific, Inc. (TMO)

From the record

Thermo Fisher Scientific, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Thermo Fisher Scientific, Inc.'s 10 filed years say what it did: revenue went from $18 billion in fiscal 2016 to $45 billion in fiscal 2025, up 10.4% a year; it rose in 8 of 9 years; the deepest fall was 5% from fiscal 2022 to fiscal 2023; net income was positive in 3 of 3 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Thermo Fisher Scientific, Inc.'s diluted share count shrank about 1.4% a year, and dividends and buybacks returned about 47% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 144 sales (132 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Thermo Fisher Scientific, Inc. earned about 13 cents of profit for every dollar of shareholders' money. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count shrank 1.3% over the year (the filed statements).

From the record

Thermo Fisher Scientific, Inc.'s standing among 11 graded names in its industry family: revenue of $45 billion in fiscal 2025 ranks in the top 5% by size; a net margin of 15% ranks in the top 23%; revenue growth of -0.3% a year over the last 3 filed years ranks in the bottom 35% (its annual reports).

From the record

Thermo Fisher Scientific, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Casper, Marc N (Chairman & CEO, as filed), filing under that title since 2009-11-12, 17 years (top 5% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 5.8 years (top 45%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Thermo Fisher Scientific, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $9.9 billion against debt of $36 billion leaves -23.6% of its assets as net cash, bottom 5% of its family; cash from operations less capital spending is 14.1% of revenue (top 25%); research spending of 3.1% of revenue (bottom 5%) (its annual report).

From the record

Thermo Fisher Scientific, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.3% a year over the last three filed years against 10.4% over all 10, slowing (bottom 15% of its family); the newest year grew 3.9% (top 41%); research spending grew -1.7% a year (bottom 41%); capital spending grew -12.1% a year (top 50%) (its annual reports). Thermo Fisher Scientific, Inc. reported 4 lines of business in fiscal 2025: Laboratory Products and Biopharma Services at $24 billion (54%), Life Sciences Solutions at $8.8 billion (20%), Analytical Instruments at $7.4 billion (17%), and 1 more; 4 of 4 grew against the year before (its annual report).

From the record

Thermo Fisher Scientific, Inc.'s newest year against its own record: revenue of $45 billion in fiscal 2025 came in 6.3% above the $42 billion its prior three years' pace pointed to (top 50% of its family); net income of $6.7 billion against a prior three-year average of $6.2 billion (top 35%); a net margin of 15% against 14.4% before (bottom 45%) (its annual reports).